Disease · MONDO_0005384

focal epilepsy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. focal epilepsy. Diseases, record MONDO_0005384. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005384

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: focal epilepsy; Open Targets
Open Targets ID: MONDO_0005384; Open Targets
Other names: epilepsies, partial, partial epilepsies, partial epilepsy; Open Targets
Disease Ontology: DOID:2234; Disease Ontology
MeSH: D004828; MeSH
NCI Thesaurus: C122812; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 19 drugs, from ClinicalTrials.gov, DailyMed and EMA Human Drugs; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZONISAMIDE	CHEMBL750	Small molecule	Approval	EMA Human Drugs	5	4	4	Drugs and targets
OXCARBAZEPINE	CHEMBL1068	Small molecule	Approval	ClinicalTrials.gov	4	4	4	Drugs and targets
PERAMPANEL	CHEMBL1214124	Small molecule	Approval	EMA Human Drugs	4	3	3	Drugs and targets
LACOSAMIDE	CHEMBL58323	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
CARBAMAZEPINE	CHEMBL108	Small molecule	Approval	DailyMed	10	1	1	Drugs and targets
VIGABATRIN	CHEMBL89598	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ESLICARBAZEPINE ACETATE	CHEMBL87992	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
BRIVARACETAM	CHEMBL607400	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CARISBAMATE	CHEMBL2087003	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets72

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN10A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6334	Drugs and targets
SCN9A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel alpha subunit inhibitor	Approval	https://conductscience.org/library/genes/6335	Drugs and targets

1 to 10 of 72

See all 72 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00477295	A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy	Phase 3	583	2013-02-08	Epilepsy	CARBAMAZEPINE, ZONISAMIDE	Its record names the disease	ClinicalTrials.gov
NCT00957047	Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy	Phase 3	395	2013-08-05	Partial Epilepsy	ESLICARBAZEPINE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00699972	Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures	Phase 3	390	2013-02-05	Refractory Partial Seizures	PERAMPANEL	Its record names the disease	ClinicalTrials.gov
NCT03796962	A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy	Phase 2	325	2024-09-24	Focal Epilepsy	AZETUKALNER	Its record names the disease	ClinicalTrials.gov
NCT00957372	Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy	Phase 3	253	2013-08-05	Partial Epilepsy	ESLICARBAZEPINE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00908349	Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy	Phase 3	214	2017-05-31	Partial Epilepsy	OXCARBAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT00866775	Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs	Phase 3	193	2016-02-04	Epilepsy With Simple or Complex Partial Onset Seizures	ESLICARBAZEPINE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01140867	Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy	Phase 4	121	2011-09-08	Epilepsy	ZONISAMIDE	Its record names the disease	ClinicalTrials.gov
NCT03283371	Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy	Phase 2	67	2021-04-27	Epilepsy, Focal Seizures, Partial Seizures	NATALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01190098	Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy	Phase 4	59	2016-12-05	Partial Epilepsy	LACOSAMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Zonisamide vs Carbamazepine: serious adverse events	15 of 281	17 of 300	581	NCT00477295	Trial comparisons
Eslicarbazepine 1200 mg QD vs Eslicarbazepine 1600 mg QD: serious adverse events	4 of 65	8 of 128	193	NCT00866775	Trial comparisons
Natalizumab 300 mg (Placebo-controlled Phase) vs Placebo (Placebo-controlled Phase): Number of Participants Free From Seizures During Weeks 8 to 24 of Treatment	0 of 31	1 of 34	65	NCT03283371	Trial comparisons
UCB0942/UCB0942 (SS) vs Placebo/UCB0942 (SS): Number of Subject Withdrawals Due to Adverse Events (AEs) During the Course of the Study	1 of 28	0 of 27	55	NCT02495844	Trial comparisons
UCB0942/UCB0942 (SS) vs Placebo/UCB0942 (SS): Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study	2 of 28	0 of 27	55	NCT02495844	Trial comparisons
UCB0942/UCB0942 vs Placebo/UCB0942: deaths from any cause	0 of 28	0 of 27	55	NCT02495844	Trial comparisons
UCB0942/UCB0942 vs Placebo/UCB0942: serious adverse events	2 of 28	0 of 27	55	NCT02495844	Trial comparisons
Lacosamide vs Sugar Pill: serious adverse events	3 of 42	0 of 10	52	NCT01190098	Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37812429	RESULT	1	PubMed
22843280	RESULT	1	PubMed
21883097	RESULT	1	PubMed
17369059	RESULT	1	PubMed
8956919	RESULT	1	PubMed
8764816	RESULT	1	PubMed
8641230	RESULT	1	PubMed
37842826	DERIVED	1	PubMed
37059702	DERIVED	2	PubMed
35305920	DERIVED	2	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005384

GET https://conductscience.org/api/diseases/v1/MONDO_0005384/targets?page=2

API reference For AI assistants